[HTML][HTML] Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: a direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude …
J Tan, M Li, W Zhong, C Hu, Q Gu, Y Xie - Oncotarget, 2017 - ncbi.nlm.nih.gov
Brain metastasis is an increasing problem in non-small cell lung cancer (NSCLC) patients.
Tyrosine kinase inhibitors (TKIs), including gefitinib, erlotinib, and icotinib, are reported to be …
Tyrosine kinase inhibitors (TKIs), including gefitinib, erlotinib, and icotinib, are reported to be …
Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis
Y Chen, M Wang, W Zhong, J Zhao - Lung Cancer, 2013 - Elsevier
Introduction Some studies showed that epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor gefitinib could improve the outcome of non-small-cell lung cancer (NSCLC) …
kinase inhibitor gefitinib could improve the outcome of non-small-cell lung cancer (NSCLC) …
A comparison between first-, second-and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer and …
S Caponnetto, O Cantale, A Friedlaender… - Journal of Molecular …, 2021 - mdpi.com
Patients with non-small-cell lung cancer (NSCLC), harboring Epidermal Growth Factor
Receptor (EGFR) mutations, are more susceptible to brain metastases (BM). Comparisons of …
Receptor (EGFR) mutations, are more susceptible to brain metastases (BM). Comparisons of …
Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
K Liu, G Jiang, A Zhang, Z Li, J Jia - BMC cancer, 2020 - Springer
Background The prognosis of non-small-cell lung cancer (NSCLC) with brain metastases is
very poor. Currently, therapeutic methods for this patient population include whole-brain …
very poor. Currently, therapeutic methods for this patient population include whole-brain …
Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or …
S Heon, BY Yeap, GJ Britt, DB Costa, MS Rabin… - Clinical cancer …, 2010 - AACR
Purpose: Gefitinib and erlotinib can penetrate into the central nervous system (CNS) and
elicit responses in patients with brain metastases (BM) from non–small cell lung cancer …
elicit responses in patients with brain metastases (BM) from non–small cell lung cancer …
Cerebral penetration of gefitinib in patients with lung adenocarcinoma.
M Wang, Z Jing, C Minjiang - Journal of Clinical Oncology, 2011 - ascopubs.org
7608 Background: Central nervous system (CNS) metastases are usually associated with
poor prognosis in the patients with non-small cell lung cancer (NSCLC). And in this situation …
poor prognosis in the patients with non-small cell lung cancer (NSCLC). And in this situation …
[HTML][HTML] Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present …
C Proto, M Imbimbo, R Gallucci, A Brissa… - … lung cancer research, 2016 - ncbi.nlm.nih.gov
Lung cancer is one of the major causes of cancer related mortality worldwide. Brain
metastases (BM) complicate clinical evolution of non-small cell lung cancer (NSCLC) in …
metastases (BM) complicate clinical evolution of non-small cell lung cancer (NSCLC) in …
The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer
H Bai, B Han - OncoTargets and therapy, 2017 - Taylor & Francis
Brain metastases are usual in non-small-cell lung cancer (NSCLC) with poor prognosis and
few available therapeutic options. This retrospective study aims to evaluate the efficacy of …
few available therapeutic options. This retrospective study aims to evaluate the efficacy of …
An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib
Y Zhang, H Tang, J Li, M Li - OncoTargets and therapy, 2015 - Taylor & Francis
Lung cancer has the highest mortality rate of all cancers worldwide. A total of 70%–75% of
all lung cancers are non-small cell lung cancer (NSCLC) with two-thirds presenting with …
all lung cancers are non-small cell lung cancer (NSCLC) with two-thirds presenting with …
[HTML][HTML] Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer …
LL Kong, LL Wang, LG Xing, JM Yu - Chronic Diseases and Translational …, 2017 - Elsevier
Non-small cell lung cancer (NSCLC) continues to be one of the major causes of cancer-
related deaths worldwide, and brain metastases are the major cause of death in NSCLC …
related deaths worldwide, and brain metastases are the major cause of death in NSCLC …